To assess the potential of B7-H3 as a therapeutic target in CRC, we firstly analyzed its transcription level using The Cancer Genome Atlas (TCGA) database and found a significant higher expression of B7-H3 in tumor tissue compared to paratumor tissue in CRC (Fig. S1A), whereas Claudin18.2 showed minimal expression in CRC compared to upper gastrointestinal tract cancers such as gastric and pancreatic cancers (Fig. S1B). The gene discussed is CD276; the disease is neoplasm.